Puma Biotechnology, Inc. (PBYI)
10.29
+0.32
(+3.21%)
USD |
NASDAQ |
Oct 09, 16:00
10.29
0.00 (0.00%)
After-Hours: 20:00
Puma Biotechnology Cash from Investing (Quarterly) : 7.972M for June 30, 2026
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 7.972M |
| March 31, 2026 | 2.474M |
| December 31, 2025 | -26.98M |
| September 30, 2025 | 0.506M |
| June 30, 2025 | -11.25M |
| March 31, 2025 | 1.531M |
| December 31, 2024 | -2.32M |
| September 30, 2024 | 0.259M |
| June 30, 2024 | 0.703M |
| March 31, 2024 | -19.08M |
| December 31, 2023 | -8.17M |
| September 30, 2023 | 11.18M |
| June 30, 2023 | -4.683M |
| March 31, 2023 | -17.45M |
| December 31, 2022 | -11.87M |
| September 30, 2022 | 7.998M |
| June 30, 2022 | 1.997M |
| March 31, 2022 | 8.982M |
| December 31, 2021 | 4.621M |
| September 30, 2021 | -4.47M |
| June 30, 2021 | -5.731M |
| March 31, 2021 | -5.301M |
| December 31, 2020 | 0.823M |
| September 30, 2020 | -2.578M |
| June 30, 2020 | -9.219M |
| Date | Value |
|---|---|
| March 31, 2020 | 34.38M |
| December 31, 2019 | -0.432M |
| September 30, 2019 | 38.97M |
| June 30, 2019 | 11.21M |
| March 31, 2019 | -44.58M |
| December 31, 2018 | 2.582M |
| September 30, 2018 | -21.36M |
| June 30, 2018 | -38.80M |
| March 31, 2018 | -0.04M |
| December 31, 2017 | -23.52M |
| September 30, 2017 | 44.08M |
| June 30, 2017 | 18.08M |
| March 31, 2017 | -54.07M |
| December 31, 2016 | 20.84M |
| September 30, 2016 | 29.47M |
| June 30, 2016 | 10.43M |
| March 31, 2016 | 81.46M |
| December 31, 2015 | 39.68M |
| September 30, 2015 | -4.746M |
| June 30, 2015 | -68.12M |
| March 31, 2015 | -52.68M |
| December 31, 2014 | 22.20M |
| September 30, 2014 | -2.771M |
| June 30, 2014 | -90.65M |
| March 31, 2014 | 7.943M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Arcutis Biotherapeutics, Inc. | -15.22M |
| ACADIA Pharmaceuticals, Inc. | -8.529M |
| Alnylam Pharmaceuticals, Inc. | -363.46M |
| Savara, Inc. | 32.60M |
| Vericel Corp. | -2.82M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 1.624M |
| Cash from Financing (Quarterly) | -11.34M |
| Free Cash Flow | 41.16M |
| Free Cash Flow Per Share (Quarterly) | 0.0309 |
| Free Cash Flow to Equity (Quarterly) | 12.76M |
| Free Cash Flow to Firm (Quarterly) | 1.803M |
| Free Cash Flow Yield | 7.77% |